CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,026 enrolled
Drug / intervention
Rimegepant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01430442
NCT01430442Phase 2Completed
CompareCT.gov

Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine

Pfizer·interventional·Posted Sep 8, 2011·Updated Feb 28, 2023

In Brief

A Phase 2 clinical trial evaluating Rimegepant, Placebo, and 1 other intervention for Migraine and Acute Treatment of Migraine. Completed, enrolled 1,026 participants across 41 sites.

Detailed Summary

The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Acute Treatment of Migraine
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 8, 2011
Enrollment StartOct 1, 2011
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.8 years ago

Interventions

Rimegepantdrug

Rimegepant capsules

Placebodrug

Rimegepant placebo-matching capsules

Sumatriptandrug

Rimegepant matching sumatriptan and Rimegepant matching placebo capsules